All News
Secukinumab Use in Refractory Giant Cell Arteritis
In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/HkMT9QEMg8
Dr. John Cush RheumNow ( View Tweet)
2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia
A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA https://t.co/STmuNO3c2Z
Dr. John Cush RheumNow ( View Tweet)
⌛️ Diagnostic delay in #SpA: Better with time?
🔹️Data from the @Official_ASAS
Study
🔹️4339 patients
🔹️Delay decreased over time
🔹️Same trends across world regions & across Human Development Index categories
POS0908 #EULAR2025
@RheumNow https://t.co/Y9gxQDV9KJ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
EULAR Points to consider for the definition of D2M and TR #Psoriatic_Arthritis
Presented by Dr Helena Marzo-Ortega at #EULAR2025
@RheumNow https://t.co/3LsJvSiXJV
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Sometimes you hear:
“PMR dose steroids don’t really matter”
Errrrr…
(You wouldn’t accept this steroid exposure in any other disease. Never)
#EULAR2025 POS0139 @RheumNow https://t.co/o6w2RpaGBj
David Liew drdavidliew ( View Tweet)
In the United States, IL-6R inhibitors have continued to help PMR patients get off steroids.
Hopefully more use and more options mean that, in the future, PMR patients get no more steroids than PsA or RA patients
#EULAR2025 POS0948 @RheumNow https://t.co/JT7gFDC5rl
David Liew drdavidliew ( View Tweet)
The new (provisional) 2025 EULAR/ACR classification criteria for anti-synthetase syndrome
#EULAR2025 @RheumNow https://t.co/X6VjcN8XZe
Links:
David Liew drdavidliew ( View Tweet)
@RheumNow EULAR haemochromatosis arthropathy classification criteria
Patrick Kiely: please photograph this and take it back to your communities
Patient association lead comes to the microphone, and thanks them for making be seen. 🥲
#EULAR2025 @RheumNow https://t.co/9bqdV0fuPk
David Liew drdavidliew ( View Tweet)
Management of SLE:
-Treat early to prevent organ damage
-Taper GC to <5mg/d in the first 6m when feasible
-New therapies are promising but still unmet needs in LN, limited global access and lacking data in pregnancy.
#EULAR2025 @RheumNow https://t.co/UKK8sTYJD2
Links:
Adela Castro AdelaCastro222 ( View Tweet)
-Difficult to treat RA is a heterogeneous concept
-Risk fx: younger onset, high disease activity,erosive disease, comorbidities, depression.
-Study in a Spanish cohort with D2T 2/2 inefficacy showed Rituximab, JAKis, and IL-6i had longer survival (hence better tx options).
-The https://t.co/ZCZcX9FRfb
Adela Castro AdelaCastro222 ( View Tweet)
Impact of TNFi on efficacy of Vunakizumab in AS.
-Post hoc analysis of Vunakizumab
(humanized monoclonal IgG1/k antibody targeting IL-17A) trial on AS pts.
-440 total pts, 163 had prior TNFi exposure
- At week 16, no significant differences in ASAS20 b/w TNFi exposed pts https://t.co/O9PFOuLa5l
Adela Castro AdelaCastro222 ( View Tweet)
#EULAR2025 Abstr#OP0041 FcRn-inhibition is showing consistency in #Sjogren. Last year it was Nipocalimab. This proof-of-concept study showed efgartigimod met its primary endpoint, the CRESS response. No difference in ESSPRI. Phase 3 UNITY is underway @RheumNow https://t.co/jw1i4FqkIh
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2025 Abstr#OP0035 SGLT2-i and GLP-1 agonist are increasingly used to treat diabetes. Population based study in Canada showed no significant difference in risk of developing an autoimmune rheumatic disease with GLP-1-RA or SGLT2i relative to DPP4i treatment @RheumNow https://t.co/CvPcOqehtl
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2025 Abstr#OP0202 Phase 1/2 of Resel-cel, a 4-1BB-containing human CD19-CAR T cell (weight-based 1 x infusion) reported efficacy in 8 patients (#SLE and LN) at WK28. 2 x Grade 1 CRS & 1 x Grade 4 ICANS. 1 x HLH, not attributed to SLE flare. Need longterm data @RheumNow https://t.co/COCKlqw687
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2025 Abstr#OP0265 Do we have convenient biomarkers to help predict new ANA+ referral who would progress to #SLE #Sjogren at 12 mths? Proteomics analysis identified IFN and B-cell markers. Validation is needed and to incorporate clinical items into prognostic model @RheumNow https://t.co/TWClLTKQ0b
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2025 Abstr#POS0318 Single timepoint assessment may not show true picture of #SLE control. Data from BILAG-BR registry using machine learning showed 6 trajectories with clinical meaning:
-Nonresponse with high activity: dsDNA-ve & RNP+
-Response-flare: active MSK @RheumNow https://t.co/VrI8e4ONtM
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#WIN in systemic sclerosis (SSc):
-Ongoing trials now targeting multiple pathways.
-CONQUEST platform may reshape research in Ssc and other autoimmune diseases.
-Revised CRISS could replace single organ endpoints for approval.
#EULAR2025
@RheumNow https://t.co/kxSeFb5lAU
Links:
Adela Castro AdelaCastro222 ( View Tweet)
+RCT in #pSjD #Sjogrens #Disease
#Leflunomide + #hydroxychloroquine
Vs #PBO
2nd study to show this - same group
need to know
▶️what pt to use this in
▶️is there diff organ improvements
⬆️#ESSDAI
⬇️RF ⬇️Ig’s
Easy to prescribe
?early, mild dx
#EULAR2025 @RheumNow @eular_org https://t.co/JE0VyFRXc6
Links:
Janet Pope Janetbirdope ( View Tweet)
#EULAR2025 Based on the updated EULAR Guidelines on #lupus nephritis, should all patients receive early Combination therapies for remission induction? @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In BIODOPT study (RA, PsA, axSpA), disease activity-guided tapering of biologics (incl. biosimilars) maintained QALY (Δ0.008, NS) while lowering biologic costs (Δ€–1,979 [95%CI –3,798;–161]) & total hospital costs (Δ€–1,936 [95%CI –3,753;–119]) over 18mo. Supports https://t.co/CJUpfU2oRA
Antoni Chan MD (Prof) synovialjoints ( View Tweet)